Access cutting-edge heart disease treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.
Access heart disease specialists in Baltimore at no cost
This study follows strict safety protocols and ethical guidelines
All study-related heart disease treatment provided free
Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging. The product was approved in 2022 by FDA to be used to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system). However, given its at
Sponsor: Johns Hopkins University
Check if you qualify for this heart disease clinical trial in Baltimore, MD
If you're searching for heart disease treatment options in Baltimore, MD, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.